Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News New warnings over Herceptin cost

New warnings over Herceptin cost

1st December 2005

Widespread use of the breast cancer drug Herceptin could cripple health authorities, a new study has warned.

Published in the Annals of Oncology, the study by European academics advises health authorities not to rush into prescribing the drug until its costs have been considered.

Currently, the drug costs around ?21,000 a year for each patient. It is estimated that up to 5,000 women could be suitable for the treatment each year, bringing the total bill to ?107 million per annum.

The academics warn that trusts will only be able to afford this if they can re-allocate resources and cut some services.

Herceptin is currently used to treat patients with advanced breast cancer although it is thought to be effective in treating early stage cancers in some women.

At present, individual trusts can choose to prescribe the treatment for women with early stage cancers, but in practice few do so because of the cost.

Following several high-profile cases, the government has said that the National Institute of Clinical Excellence (NICE) will fast-track approval for the drug when its manufactures apply for a license.

The new findings suggest that even with official approval from NICE, some trusts may be reluctant to embrace the treatment.

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.